coronavirus June 14, 2021 9:57 am Novavax Says Its Vaccine Has 90.4% Efficacy Novavax announced Monday that its COVID-19 vaccine had a 90.4% efficacy in a phase 3 trial in the U.S. and Mexico. US & World Videos 1:43 How to tell if it's COVID, flu or fall allergies and what to do 1:59 New COVID-19 vaccines, free tests available as cases rise 1:31 CDC recommends updated Covid shot for everyone ages 6 months and up 1:33 People weigh updated COVID-19 boosters as FDA potential approval nears 2:26 COVID-19 Public Health Emergency Ends in Connecticut